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We have previously shown that non-pathogenic Gram-
negative Bacteroides vulgatus induces transient RelA
phosphorylation (Ser-536), NF-B activity, and pro-
inflammatory gene expression in native and intestinal
epithelial cell (IEC) lines. We now demonstrate that 15-
deoxy-12,14-prostaglandin J2 (15d-PGJ2) but not pros-
taglandin E2 inhibits lipopolysaccharide (LPS) (B. vul-
gatus)/LPS (Escherichia coli)-induced RelA phos-
phorylation and interleukin-6 gene expression in the
colonic epithelial cell line CMT-93. This inhibitory effect
of 15d-PGJ2 was mediated independently of LPS-
induced IB phosphorylation/degradation and RelA
nuclear translocation as well as RelA DNA binding ac-
tivity. Interestingly, although B. vulgatus induced nu-
clear expression of peroxisome proliferator-activated
receptor  (PPAR) in native epithelium of monoassoci-
ated Fisher rats, PPAR-specific knock-down in CMT-93
cells using small interference RNA failed to reverse the
inhibitory effects of PPAR agonist 15d-PGJ2, suggest-
ing PPAR-independent mechanisms. In addition, 15d-
PGJ2 but not the synthetic high affinity PPAR ligand
rosiglitazone triggered ERK1/2 phosphorylation in IEC,
and most importantly, MEK1 inhibitor PD98059 re-
versed the inhibitory effect of 15dPGJ2 on LPS-induced
RelA phosphorylation and interleukin-6 gene expres-
sion. Calyculin A, a specific phosphoserine/phospho-
threonine phosphatase inhibitor increased the basal
phosphorylation of RelA and reversed the inhibitory
effect of 15d-PGJ2 on LPS-induced RelA phosphoryla-
tion. We further demonstrated in co-immunoprecipita-
tion experiments that 15d-PGJ2 triggered protein phos-
phatase 2A activity, which directly dephosphorylated
RelA in LPS-stimulated CMT-93 cells. We concluded that
15d-PGJ2 may help to control NF-B signaling and nor-
mal intestinal homeostasis to the enteric microflora by
modulating RelA phosphorylation in IEC through al-
tered protein phosphatase 2A activity.
The mucosal surfaces and cavities of the gastrointestinal
tract in humans and animals are populated by a complex mix-
ture of non-pathogenic microorganisms of more than 400 spe-
cies having spatial differences in population size and relative
species predominance along the digestive tract (1–4). The host
has evolved various homeostatic mechanisms to acquire toler-
ance (hyporesponsiveness) to resident enteric microorganisms,
whereas protective cell-mediated and humoral immune re-
sponses to enteropathogens are maintained. This complex ho-
meostasis toward the normal enteric microflora is broken un-
der conditions of chronic intestinal inflammation including the
chronically relapsing, immune-mediated idiopathic disorders
ulcerative colitis and Crohn’s disease (5, 6). The selective effect
of microbial factors in initiating and perpetuating chronic in-
testinal inflammation is extensively supported in comparative
studies using germ-free and gnotobiotic rodent models for ex-
perimental colitis (7). For example, reconstitution studies with
various non-pathogenic bacteria implicate Bacteroides vulga-
tus as particularly important to the induction of experimental
colitis in monoassociated HLA-B27 transgenic rats (8, 9).
Increased NF-B activity has been well documented in in-
testinal epithelial cell (IEC)1 and lamina propria cells of in-
flammatory bowel disease patients with active disease (10–12),
and accordingly, pharmacological NF-B blockade may become
potentially important in the treatment of chronic intestinal
inflammation (13, 14). Indeed, local administration of anti-
sense RelA oligonucleotides abrogated clinical and histological
signs of trinitrobenzene sulfonic acid-induced experimental co-
litis, suggesting a mechanistic role for sustained NF-B activ-
ity in the pathogenesis of chronic mucosal inflammation (15).
On the other hand, blocking NF-B activity with pharmacolog-
ical inhibitors during the resolution phase of carrageenan-
induced acute inflammation is deleterious to the host (16),
suggesting dual functions of activated NF-B including protec-
tive and detrimental mechanisms during the course of
inflammation.
The induction of the IB/NF-B system and NF-B-depend-
ent gene expression is a complex process that involves the
participation of multiple adaptor proteins and kinases acting in
a coordinate fashion to give specificity to the cell surface stim-
uli. We have previously shown that B. vulgatus and lipopoly-
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saccharide (LPS) signal through the TLR4 cascade to trigger
IRAK1 degradation and IB phosphorylation/degradation as
well as NF-B DNA binding activity and NF-B transcriptional
activity in native and IEC lines (17). In addition to the activa-
tion of the IB/NF-B system and nuclear translocation of
transcriptionally active RelA, the modification of NF-B tran-
scriptional activity by phosphorylation of RelA at various ser-
ine residues (Ser-276, Ser-529, Ser-536) has been shown to be
an important regulatory element of this signaling pathway
(18–21). Potential kinases involved in signal-induced RelA
phosphorylation are the casein kinase II, Akt, and IKK. We
showed that IKK and the phosphatidylinositol 3-kinase/Akt
pathway participate in B. vulgatus-induced phosphorylation of
serine 529 and/or 536 of the RelA transactivating domain 1
(TAD1) in IEC (17). Most importantly for the physiological
relevance, we showed that monoassociation of wild type rats
with B. vulgatus triggered transient nuclear localization of
phosphorylated (Ser-536) and transcriptionally active NF-B
subunit RelA (p65) in the intestinal epithelium (17, 22). The
absence of colitis and pathological immune responses in B. vul-
gatus-monoassociated wild type rats confirmed the non-patho-
genic nature of this obligate anaerobic Gram-negative bacterial
strain and suggests that the normal host developed mecha-
nisms to control NF-B activity in IEC (23).
Protein serine/threonine phosphatases including PP1, PP2A,
PP2B, and PP2C are involved in the regulation of signaling
pathways with a variety of protein kinases (24, 25). PP2A has
been shown to form a complex with calcium/calmodulin-de-
pendent protein kinase IV (26), casein kinase (27), p21-acti-
vated kinase-1 and -3, and p70 S6 kinase (28) as well as certain
G-protein-coupled receptors (29, 30). Recently, PP2A was
shown to interact with and directly dephosphorylate RelA,
suggesting PP2A as an important regulator of NF-B signaling
(31, 32). The predominant heterotrimeric form of PP2A consists
of the 36-kDa catalytic subunit (PP2Ac) and a 65-kDa regula-
tory subunit (PP2Aa or PR65). In addition, several regulatory
subunits are associated with the core enzyme, conferring sub-
strate specificity to its dephosphorylating activity (24, 25).
Peroxisome proliferator-activated receptor  (PPAR) is a
member of the steroid receptor superfamily with various cellu-
lar functions including differentiation, apoptosis, lipid metab-
olism, and anti-inflammatory responses (33–35). Although
PPAR is expressed in multiple tissues, the highest levels are
found in adipose tissue and colonic epithelium (36). Ligand-
specific activation of the PPAR transcription factor has been
shown to inhibit pro-inflammatory gene expression and exper-
imental colitis for synthetic anti-diabetic thiazolidinediones
(TZDs) including rosiglitazone and troglizitazone as well as the
endogenous prostaglandin D2 metabolite 15-deoxy-
12,14-pros-
taglandin J2 (15d-PGJ2) (37–42). It appears from several stud-
ies that TZD and 15d-PGJ2, which is present in vivo during the
resolution phase of acute inflammation (43), mediate their
anti-inflammatory effects also through PPAR-independent
mechanisms affecting the NF-B signaling pathway at the
level of IKK activity and IB degradation as well as RelA
DNA binding activity (37, 44, 45).
In this study we characterized the molecular mechanism for
the inhibitory effect of 15d-PGJ2 on RelA phosphorylation (Ser-
536) and IL-6 gene expression in IEC. Consistent with the
transient induction of phospho-RelA (Ser-536) in the intestinal
epithelium of B. vulgatus-monoassociated Fisher rats, 15d-
PGJ2 but not the synthetic high affinity PPAR ligand rosigli-
tazone inhibited LPS (B. vulgatus)/LPS (Escherichia coli)-in-
duced RelA phosphorylation and IL-6 gene expression in
CMT-93 cells. Although B. vulgatus triggered nuclear expres-
sion of PPAR in native epithelium of monoassociated Fisher
rats, PPAR-specific knock-down in CMT-93 cells using small
interference RNA failed to reverse the inhibitory effects of
PPAR agonist 15d-PGJ2, suggesting PPAR-independent
mechanisms. Finally, we could demonstrate that 15d-PGJ2 in-
hibits LPS-induced RelA phosphorylation and IL-6 gene ex-
pression in IEC through the induction of the ERK signaling
cascade by modulating PP2A activity.
MATERIALS AND METHODS
Animals and Bacterial Monoassociation—Germ-free Fisher F344
rats were monoassociated at 10–12 weeks of age with B. vulgatus (a
generous gift from Dr. A. B. Onderdonk, Harvard University, Cam-
bridge, MA) and maintained in the Gnotobiotic Animal Core at the
College of Veterinary Medicine, North Carolina State University (Ra-
leigh, NC). Bacterial monoassociation and the absence of contamination
by other bacterial species were confirmed by culturing samples from the
large intestine at necropsy and culturing serial fecal samples. Animal
use protocols were approved by the Institutional Animal Care and Use
Committee (IACUC), North Carolina State University. Rats were killed
3, 7, 14, and 35 days after initial bacterial colonization. Germ-free mice
were used as controls. Sections of the ileum, cecum, proximal, and distal
colon were fixed in 10% neutral buffered formalin. The fixed tissue was
embedded in paraffin. Histology scoring was analyzed by blindly as-
sessing the degree of lamina propria mononuclear cell infiltration, crypt
hyperplasia, goblet cell depletion, and architectural distortion.
Immunohistochemistry and Isolation of Primary Rat Intestinal Epi-
thelial Cells—B. vulgatus-monoassociated and germ-free rats were eu-
thanized, and the cecum as well as colon were removed and placed in
Dulbecco’s modified Eagle’s medium (Invitrogen) containing 5% fetal
calf serum. Cecum and colon were cut longitudinally, washed three
times in calcium/magnesium-free Hanks’ balanced salt solution (In-
vitrogen), cut into pieces 0.5 cm long, and incubated at 37 °C in 40 ml of
Dulbecco’s modified Eagle’s medium containing 5% fetal calf serum and
1 mM dithiothreitol for 30 min in an orbital shaker. The supernatant
was filtered and centrifuged for 5 min at 400  g, and the cell pellet was
resuspended in Dulbecco’s modified Eagle’s medium containing 5% fetal
calf serum. The remaining tissue was incubated in 30 ml of phosphate-
buffered saline (1) containing 1.5 mM EDTA for an additional 10 min.
The supernatant was filtered and centrifuged for 5 min at 400  g, and
the cell pellet was resuspended in Dulbecco’s modified Eagle’s medium
containing 5% fetal calf serum. Finally, primary IEC were collected by
centrifugation through a 25/40% discontinuous Percoll gradient at
600  g for 30 min. Cell viability and purity was assessed by trypan
blue exclusion and fluorescence-activated cell sorter analysis using
mouse anti-CD3 monoclonal antibody (BD Biosciences Pharmingen,
clone G4.18). Cells were 80% viable and 90% pure. Primary rat IEC
from cecum and colon were combined and collected in sample buffer for
subsequent Western blot analysis. Immunohistochemistry on paraffin-
embedded tissue sections was performed using anti-PPAR Ab (Cell
Signaling, Beverly, MA) according to the protocol of the manufacturer,
and sections were counterstained with hematoxylin.
Cell Culture and Bacterial Infection—The IEC line CMT-93 (passage
10–30) (ATCC CRL 223, American Type Culture Collection) was grown
in a humidified 5% CO2 atmosphere at 37 °C to confluency in 6-well
tissue culture plates (Cell Star, Greiner bio-one, Frickenhausen, Ger-
many) as previously described (17). B. vulgatus was anaerobically
grown at 37 °C in brain-heart infusion broth. Bacteria were harvested
by centrifugation (3000  g, 15 min) supplemented with cysteine
(0.05%), hemin (5 mg/liter), and resazurin at stationary growth phase.
For LPS purification, B. vulgatus was killed by the addition of 1%
phenol (Fluka, Heidelberg) and washed thoroughly with twice-distilled
water. Endotoxin was extracted and purified by the method of Westphal
et al. (26). Purity was checked by SDS-PAGE (46). Confluent epithelial
cell monolayers were stimulated with B. vulgatus LPS (10 g/ml) and
E. coli LPS (10 g/ml; from E. coli serotype O111:B4, Sigma) in the
presence or absence of 20 M 15d-PGJ2 (BioMol, Plymouth Meeting, PA)
and 20 M rosiglitazone (BioMol). Where indicated, cells were treated
with 20 M MEK1 inhibitor PD98059 (Calbiochem) or 1–5 nM calyculin
A (Cell Signaling).
RNA Isolation and Real-time Reverse Transcription-PCR—RNA from
IEC was extracted using Trizol reagent (Invitrogen) according to the
manufacturer’s instructions. Extracted RNA was dissolved in 20 l of
water containing 0.1% diethyl pyrocarbonate. For reverse transcription,
1 g of total RNA was added to 30 l of reaction buffer containing 8 l
of 5 first-strand buffer, 4 l of dithiothreitol (100 mM), and 6 l of
deoxyribonucleoside triphosphate mixture (300 M) (all reagents from
Invitrogen) and incubated for 5 min at 65 °C. After adding 10 l of a
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solution containing 0.2 g of random hexamers, 40 units of RNase Out,
and 200 units of Moloney murine leukemia virus reverse transcriptase
(all reagents from Invitrogen), the total mixture was incubated for an
additional 60 min at 37 °C followed by a final 1-min heating step at
99 °C.
Real-time PCR was performed in glass capillaries using a Light
CyclerTM system (Roche Diagnostics). Primer sequences and amplicon
sizes are as follows: IL-6, 5-acaacgatgatgcactt-3 (forward) and 5cttg-
gtccttagccact-3 (reverse) (334 bp); IB, 5-gtgactttgggtgctg-3 (for-
ward) and 5-gctgtatccgggtactt-3 (reverse) (193 bp); PPAR, 5-tccgta-
gaagccgtgc-3 (forward) and 5-ggatgtcctcgatggg-3 (reverse) (364 bp);
GAPDH, 5-atcccagagctgaacg-3 (forward) and 5-gaagtcgcaggagaca-3
(reverse) (198 bp). For real-time PCR, 1 l of reverse-transcribed cDNA
was added in a total volume of 10 l of PCR reaction buffer containing
1 LC-FastStart DNA Master Mix (Roche Applied Science), MgCl2 (4
M), and forward and reverse primers (20 M). The PCR program was
one cycle of denaturation at 95 °C for 10 min followed by 50 cycles of
95 °C for 15 s, annealing at 60 °C for 10 s, and extension at 72 °C for
20 s. The amplified product was detected by the presence of a SYBR
green fluorescent signal. Melting curve analysis and gel electrophoresis
was used to document the amplicon specificity. Calibration curves were
generated by measuring serial dilutions of stock cDNA to calculate the
amplification efficiency (E). The crossing point (Cp) of the log-linear
portion of the amplification curve was determined. The relative induc-
tion of gene mRNA expression was determined using the calculation
E
Cp (control samples  treated samples)
and normalized for the expression of GAPDH
mRNA (47). Triplicate samples were measured in duplicate and blotted
as -fold increase between treated and untreated control samples.
Western Blot Analysis—IEC were lysed in 1 Laemmli buffer, and
20–50 g of protein was subjected to electrophoresis on 10% SDS-PAGE
gels. Where indicated IEC cells were pretreated for 1 h with 20 M
proteasome inhibitor MG132 (BioMol). Anti-IB (C21, Santa Cruz
Biotechnology), anti-NF-B RelA (Santa Cruz), anti-phospho-IB
(Ser-32), anti-phospho-RelA (Ser-536), anti-phospho-ERK1/2 (p44/p42)
(Tyr-202/204), ERK1/2, anti-PPAR (all antibodies from Cell Signaling,
Beverly, MA), anti-PP2A (Abcam, Cambridge, UK), and anti--actin
(ICN, Costa Mesa, CA) were used to detect immunoreactive phospho-
IB, total IB, total RelA, phospho-RelA, phospho-ERK1/2, ERK1/2,
PPAR, PP2A, and -actin, respectively, using an enhanced chemilu-
minescence light-detecting kit (Amersham Biosciences) as previously
described (17).
Small Interference RNA and Transfection—Synthetic PPAR-spe-
cific (accession number NM_011146) siRNA was designed and pur-
FIG. 1. RelA phosphorylation and PPAR expression in intestinal epithelium of B. vulgatus-monoassociated germ-free Fisher
rats. Germ-free Fisher rats (n  2) were monoassociated with B. vulgatus. Rats were killed at days 3, 7, 14, and 35 after initial bacterial
colonization. Native IEC were isolated from cecum and colon. Total protein was extracted, and 20 g protein were subjected to SDS-PAGE followed
by phospho-RelA, PPAR, and -actin immunoblotting using ECL technique (A). Sections of cecum and colon were fixed in 10% neutral-buffered
formalin. Immunohistochemistry was performed on paraffin-embedded tissue sections using anti-PPAR antibody and analyzed at 20 or 40
magnification (B and C). Sections were counterstained with hematoxylin.
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chased from Qiagen (Hilden, Germany) according to the protocol of the
manufacturer. The sequence was as follows: sense, 5-AGACCCAG-
CUCUACAACAG(TT)-3; reverse 5-CUGUUGUAGAGCUGGGUCU-
(TT)-3. The annealed double stranded ribooligonucleotides were dis-
solved in RNase-free buffer and stored at 20 °C in a concentration of
20 M. Before performing the experiments, the siRNA was heat-treated
for 1 min at 90 °C and then incubated for an additional 60 min at 37 °C.
CMT-93 cells, which were grown to 80–90% confluency, were trans-
fected with single-stranded siRNA (0.4, 0.8, or 1.6 g of total siRNA)
according to the protocol of the manufacturer using TransMessanger
reagent (Qiagen). Finally, the transfected CMT-93 cells were cultured
for an additional 48 h and then stimulated with LPS (10 g/ml) for 12 h
in the presence or absence of 15d-PGJ2. Rhodamine-stained siRNA was
used to visualize the cellular distribution in transfected CMT-93 epi-
thelial monolayers using fluorescence microscopy.
Nuclear Extracts and NF-B p65 Protein/DNA Binding Activity—
CMT-93 cells were stimulated for various times (0–4 h) with E. coli LPS
(10 g/ml), and nuclear extracts were prepared according to the man-
ufacturer’s instructions (Active Motif, Carlsbad, CA). Extracts (5 g)
were used to determine nuclear RelA binding activity to the B-nucle-
otide consensus sequence 5-GGGACTTTCC-3 by using the TransAM
ELISA-based NF-B transcription factor assay (Active Motif). Protein/
oligonucleotide binding activity was quantified by colorimetric analysis
using a MultiScan spectrophotometer.
Co-immunoprecipitation and Phosphatase Activity Assay—CMT-93
cells were stimulated with either E. coli LPS (10 g/ml) or 15d-PGJ2 (20
M). Cells were lysed in lysis buffer (50 mM Tris at pH 8.0, 2 mM EDTA,
0.1% Nonidet P-40, and 10% glycerol supplemented with protease in-
hibitors. Cell debris was removed by centrifugation at 12,000  g, and
the supernatant was precleared for 1 h with 20 l of protein A/G-
agarose (Santa, Cruz, Europe). Total protein concentration was normal-
ized, and immunoprecipitation was carried out overnight at 4 °C using
5 l of rabbit anti-phospho-RelA and goat anti-PP2A antibody (Abcam).
Immune complexes were collected with 30 l of protein A/G-agarose for
30 min, washed, and resuspended in reaction buffer (100 l) containing
20 mM HEPES (pH 7.4), 10 mM MgCl2, and 1 M dithiothreitol. To assay
the phosphatase activity, 30 l of beads from LPS-stimulated cells were
co-incubated with 50 l of beads from 15d-PGJ2-treated cells. Reactions
were stopped after 1 and 2 h of incubation at 37 °C with the addition 2
Laemmli sample buffer. Western blot analysis for phospho-RelA and
PP2A were carried out as described above.
ELISA Analysis—Protein concentrations were determined in spent
culture supernatants of IEC cultures using an ELISA technique. IL-6
protein production was determined by mouse-specific ELISA assay kits
according to the manufacturer’s instructions (R&D Systems, Heidel-
berg, Germany).
Statistical Analysis—Data are expressed as the mean  S.D. of
triplicates. Statistical analysis was performed by the two-tailed Stu-
dent’s t test for paired data and considered significant if p values were
0.05 (*) or 0.01 (**).
RESULTS
B. vulgatus-monoassociated Fisher Rats Trigger Transient
Phosphorylation of RelA and Persistent Expression of PPAR-
in Native IEC—We investigated RelA phosphorylation and
PPAR- expression in the intestinal epithelium of B. vulgatus-
monoassociated and germ-free Fisher rats. The rats were killed
after 3, 7, 14, and 35 days of initial bacterial colonization, and
native IEC were isolated from cecal and colonic tissue. Phos-
pho-RelA (Ser-536) and PPAR protein expression were meas-
ured in isolated native IEC using Western blot analysis. As
shown in Fig. 1, although B. vulgatus monoassociation of germ-
free rats triggered transient phosphorylation of RelA at day 3
in native IEC, PPAR protein expression was persistently in-
duced 3–28 days after bacterial colonization. Nuclear localiza-
tion of PPAR in cecal and colonic epithelium was confirmed in
intestinal tissue sections by performing immunohistochemical
analysis (Fig. 1, B and C).
15d-PGJ2 but Not Rosiglitazone Inhibits RelA Phosphoryla-
tion in CMT-93 Cells after Stimulation with B. vulgatus and
E. coli LPS—We have previously shown that whole B. vulgatus
cells and E. coli-derived LPS trigger RelA phosphorylation,
NF-B activity, and pro-inflammatory gene expression in IEC
lines. Based on these results, we next asked the question
whether PPAR agonists inhibit RelA phosphorylation in
CMT-93 cells. We used the endogenous prostaglandin D2 me-
tabolite 15d-PGJ2 and the synthetic PPAR ligand rosiglita-
zone to antagonize B. vulgatus LPS- and E. coli LPS-induced
RelA phosphorylation in CMT-93. Fig. 2 shows that 15d-PGJ2
inhibits RelA phosphorylation in CMT-93 cells after 1 and 2 h
of stimulation with B. vulgatus LPS (Fig. 2A) as well as E. coli
LPS (Fig. 2B). Of note, the synthetic high affinity PPAR
ligand rosiglitazone did not inhibit LPS-induced RelA phospho-
rylation. To further characterize the inhibitory mechanisms of
15d-PGJ2 on LPS-induced NF-B signaling, we used the com-
mercially available E. coli LPS.
15d-PGJ2 Failed to Inhibit LPS-induced IB Degradation,
RelA Nuclear Translocation, and RelA DNA Binding Activity in
IEC—We next investigated the effect of 15d-PGJ2 and rosigli-
tazone on LPS-induced IB degradation, RelA nuclear trans-
location, and RelA DNA binding activity in CMT-93 cells. We
stimulated the cells with LPS in the presence or absence of
15d-PGJ2 and rosiglitazone for 1 and 2 h. Fig. 3A shows that
FIG. 2. 15d-PGJ2 inhibits LPS-in-
duced RelA phosphorylation in
CMT-93 cells. CMT-93 cells were stimu-
lated with 10 g/ml LPS from B. vulgatus
(A) and E. coli (B) for 1 and 2 h in the
presence of 20 M 15d-PGJ2 and 20 M
rosiglitazone (Rosig). Total protein was
extracted, and 20 g of protein were sub-
jected to SDS-PAGE followed by phos-
pho-RelA and -actin immunoblotting
using ECL technique. The results are
representative of three independent
experiments.
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LPS-induced IB phosphorylation as well as IB degrada-
tion in CMT-93 cells after 1 h of stimulation followed by com-
plete IB resynthesis after 2 h of stimulation. Of note, 15d-
PGJ2 and rosiglitazone failed to inhibit LPS-induced IB
phosphorylation/degradation after 1 h of stimulation. Interest-
ingly and in contrast to rosiglitazone, 15d-PGJ2 blocked IB
phosphorylation after 2 h of stimulation. IB protein resyn-
thesis was not affected in the presence of any of the two PPAR
agonists.
We next studied LPS-induced nuclear translocation and
RelA DNA binding activity in the presence or absence of 15d-
PGJ2 and rosiglitazone in CMT-93 cells. As shown in Fig. 3C,
whereas LPS-induced RelA DNA binding activity was slightly
reduced after 1 h of stimulation, this moderate inhibitory effect
was completely abolished after 2 h of stimulation. Rosiglita-
zone did not affect RelA nuclear translocation or RelA DNA
binding activity (Fig. 3B).In summary, these results suggest
that 15d-PGJ2 did not affect LPS-induced IB degradation,
IB resynthesis, or RelA nuclear translocation but slightly
delayed RelA DNA binding activity in LPS-stimulated IEC.
15d-PGJ2 Selectively Inhibited IL-6 but Not IB Gene Ex-
pression in LPS-stimulated IEC—We next sought to investi-
gate the effect of 15d-PGJ2 and rosiglitazone on LPS-induced
IL-6 and IB gene expression in CMT-93 cells. Therefore, we
stimulated the cells for 12 h with LPS in the presence or
absence of 15d-PGJ2 and rosiglitazone. Interestingly, reverse
transcription and real-time PCR analysis revealed that 15d-
PGJ2 but not rosiglitazone inhibited IL-6 mRNA expression in
LPS-stimulated CMT-93 cells (Fig. 4A). Accordingly, IL-6 pro-
tein production was significantly inhibited in the presence of
FIG. 3. Effects of 15d-PGJ2 on LPS-induced IB phosphoryl-
ation/degradation, RelA nuclear translocation, and RelA DNA
binding activity. CMT-93 cells were stimulated with 10 g/ml LPS
from E. coli for 1 and 2 h in the presence or absence of 20 M 15d-PGJ2
and 20 M rosiglitazone (Rosig). Total protein was extracted, and 20 g
of protein were subjected to SDS-PAGE followed by phospho-IB,
IB, and -actin immunoblotting using an ECL technique (A). Nuclear
extracts were isolated, and 20 g of nuclear protein were subjected to
SDS-PAGE followed by RelA and -actin immunoblotting using ECL
technique (B). Nuclear extracts were isolated, and RelA DNA binding
activity was quantified using a TransAM ELISA-based NF-B tran-
scription factor assay. Protein/oligonucleotides binding activity was
determined by colorimetric analysis using 5 g of nuclear extracts (C).
The results are representative three independent experiments.
FIG. 4. 15d-PGJ2 inhibits LPS-induced IL-6 mRNA but not
IB gene expression. CMT-93 cells were stimulated with 10 g/ml
LPS from E. coli for 12 h in the presence or absence of 20 M 15d-PGJ2
and 20 M rosiglitazone (Rosig). Total RNA was extracted and reverse-
transcribed, and real-time PCR was performed using the Light Cycler
system with specific primers for murine IL-6, IB, and GAPDH. The
induction of IL-6 and IB mRNA expression was calculated relative to
untreated controls (-fold increase) using the crossing point of the log-
linear portion of the amplification curve after normalization with
GAPDH (A). CMT-93 cells were stimulated with 10 g/ml LPS from
E. coli for 36 h in the presence or absence of 20 M 15d-PGJ2 and
rosiglitazone. IL-6 was measured in the spent culture supernatant
using the ELISA method. The bars represent the combined mean values
(S.D.) of triplicate samples. B: *, p value 0.05.
15d-PGJ2 Triggers PP2A Activity in Intestinal Epithelial Cells 36107
15d-PGJ2 but not rosiglitazone (Fig. 4B). Consistent with our
previous results, IB mRNA expression was not affected in
the presence of 15d-PGJ2 or rosiglitazone.
Because 15d-PGJ2 but not the synthetic high affinity PPAR
ligand rosiglitazone displayed inhibitory effects on IEC activa-
tion, we next transfected CMT-93 cells with PPAR-specific
siRNA oligonucleotides (0.8 g). Western blot and real-time
PCR analysis confirmed PPAR-specific knock-down (80%) in
CMT-93 cells in the presence of siRNA oligonucleotides. Most
importantly, functional analysis in the presence PPAR-spe-
cific siRNA revealed no effect on 15d-PGJ2-mediated inhibition
of IL-6 gene expression, confirming PPAR-independent mech-
anisms for the inhibitory effects 15d-PGJ2 in LPS-activated
IEC (data not shown).
To further elucidate the specificity of 15d-PGJ2-mediated
inhibition of RelA phosphorylation, we stimulated CMT-93
cells with LPS in the presence or absence of 15dPGJ2 and
PGE2. As shown in Fig. 5, 15d-PGJ2 but not PGE2 blocked
LPS-induced RelA phosphorylation (Fig. 5A) as well as IL-6
mRNA expression (Fig. 5B).
15d-PGJ2-mediated Inhibition of LPS-induced RelA Phos-
phorylation and IL-6 Gene Expression Is Reversed in the Pres-
ence of MEK1 Inhibitor PD98059—The mechanisms of 15d-
PGJ2 to inhibit RelA phosphorylation and IL-6 gene expression
were independent from the presence of PPAR. It has been
previously shown that 15d-PGJ2 triggers ERK1/2 phosphoryl-
ation in murine myoblast cell line C2C12 (48). Based on these
results, we next investigated the role of the MAP kinase path-
way ERK1/2 to mediate the inhibitory effect of 15d-PGJ2 on
LPS-induced IEC activation. Interestingly, 15d-PGJ2 and LPS
but not rosiglitazone (data not shown) induced ERK1/2 phos-
phorylation in CMT-93 cells after 1 h of stimulation, whereas a
weak expression of phospho-ERK1/2 remained after 2 h of
stimulation in the presence of 15d-PGJ2 but not LPS or LPS/
15d-PGJ2 (data not shown). We then used the MEK1 inhibitor
PD98059 to inhibit ERK1/2 phosphorylation in CMT-93 cells
after the stimulation with LPS for 1 h. Fig. 6A shows that the
addition of PD98059 inhibited LPS-induced ERK phosphoryl-
ation in the presence (lane 5) and absence (lane 7) of 15d-PGJ2.
Interestingly, LPS stimulation in the presence of 15d-PGJ2
further increased ERK1/2 phosphorylation in CMT-93 cells
after 1 h of stimulation (lane 6). Consistent with our previous
results (Figs. 2 and 5), 15d-PGJ2 completely inhibited LPS-
induced RelA phosphorylation (lane 13). Most importantly, al-
though the presence of PD98059 revealed no effect on LPS-
induced RelA phosphorylation (lane 12), the presence of the
MEK1 inhibitor at least partially reversed 15d-PGJ2-mediated
inhibition of RelA phosphorylation (lane 14).
To further elucidate the role of the ERK signaling pathway
on the inhibitory effects of 15d-PGJ2, we measured LPS-in-
duced IL-6 gene expression in the presence or absence of 15d-
PGJ2 after 12 h of stimulation. Real-time RT-PCR analysis
revealed that the presence of PD98059 completely reversed
15d-PGJ2-mediated inhibition of LPS-induced IL-6 mRNA ex-
pression, whereas PD98059 alone did not affect LPS-induced
IL-6 gene expression (Fig. 6B). In conclusion, these results
suggest that 15d-PGJ2 inhibits LPS-induced RelA phosphoryl-
ation as well as IL-6 gene expression in IEC through induction
of the ERK-signaling cascade.
15d-PGJ2 Triggers Protein Phosphatase 2A Activity, Which
Directly Dephosphorylates RelA—Protein serine/threonine
phosphatase activity plays an important role in the regulation
of transcription factor activity (24, 25). To further elucidate the
role of protein serine/threonine phosphatase activity in 15d-
PGJ2-mediated inhibition of RelA phosphorylation and IL-6
gene expression, we used the specific inhibitor calyculin A.
Interestingly, the treatment of CMT-93 cells with calyculin A (5
nM) dramatically increased the basal level RelA phosphoryla-
tion after 1 h of stimulation (Fig. 7A, lane 2). The additional
treatment of CMT-93 cells with LPS did not further increase
RelA phosphorylation (Fig. 7A, lane 5). In addition and consist-
ent with our previous results, LPS-induced RelA phosphoryla-
tion was inhibited in the presence of 15d-PGJ2 (Fig. 7A, com-
pare lane 4 and 6), and most importantly, calyculin A
completely reversed this inhibitory effect of 15d-PGJ2 (Fig. 7A,
lane 7). Total PP2A was similar in all samples, suggesting that
PP2A expression remained unchanged during the different
treatments. As shown in Fig. 7B, LPS-induced IL-6 mRNA
expression was significantly increased in the presence of caly-
culin A. Similar to our previous results, 15d-PGJ2 inhibited
LPS-induced IL-6 gene expression. This inhibitory effect was
reversed in the presence of calyculin A, suggesting a role of
protein phosphatases for the inhibitory effects of 15d-PGJ2 on
RelA phosphorylation as well as IL-6 gene expression in
CMT-93 cells.
To further specify the role of 15d-PGJ2 in triggering phos-
phatase activity, we co-immunoprecipitated endogenous phos-
pho-RelA and PP2A after the treatment of CMT-93 cells with
FIG. 5. 15d-PGJ2 but not PGE2 in-
hibit LPS-induced RelA phosphoryl-
ation and IL-6 gene expression.
CMT-93 cells were stimulated with 10
g/ml LPS from E. coli in the presence or
absence of 20 M 15d-PGJ2 and 20 M
PGE2. A, total protein was extracted after
1 and 2 h of stimulation, and 20 g of
protein were subjected to SDS-PAGE fol-
lowed by phospho-RelA and -actin im-
munoblotting using ECL technique. B, to-
tal RNA was extracted after 12 h of
stimulation, reverse-transcribed, and re-
al-time PCR was performed using the
Light Cycler system with specific primers
for murine IL-6 and GAPDH. The induc-
tion of IL-6 mRNA expression was calcu-
lated relative to untreated controls (fold
increase) using the crossing point of the
log-linear portion of the amplification
curve after normalization with GAPDH.
The bars represent the combined mean
values (S.D.) of triplicate samples. *, p
value 0.05.
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LPS and 15d-PGJ2, respectively. Immunoprecipitated phos-
pho-RelA was then co-incubated with PP2A-loaded A/G-agar-
ose beads for additional 1, 2, and 4 h. As shown in Fig. 7C,
PP2A directly dephosphorylated RelA after 1, 2, and 4 h of
co-incubation, suggesting that 15d-PGJ2 triggers PP2A activity
in CMT-93 cells. Of note, total RelA and PP2A confirmed equal
loading of the samples. In conclusion, we demonstrated that
15d-PGJ2 triggered PP2A activity, which directly dephospho-
rylated RelA in LPS-stimulated CMT-93 cells.
DISCUSSION
In this study, we demonstrate that 15d-PGJ2 inhibits LPS
(B. vulgatus)/LPS (E. coli)-induced RelA phosphorylation and
IL-6 gene expression in the colonic epithelial cell line CMT-93
through induction of the MEK/ERK signaling cascade. Consist-
ent with the transient expression of phospho-RelA in native
IEC of B. vulgatus-monoassociated Fisher rats, 15d-PGJ2 trig-
gers PP2A activity, which directly dephosphorylates RelA in
LPS-stimulated CMT-93 cells.
It appears from several studies that PPAR agonists including
synthetic TZD and 15d-PGJ2 attenuate colonic inflammation in
different models of experimental colitis (41, 42, 49–51) and an-
tagonize NF-B signaling through covalent modification and in-
hibition of IKK in PPAR-independent mechanisms (37, 44, 45).
Indeed, we show PPAR-independent mechanisms for the inhib-
itory effect of 15d-PGJ2 in CMT-93 cells using siRNA-mediated
knock-down of PPAR. In addition, several studies now point
toward ligand-independent anti-inflammatory effects of PPAR.
For example, studies with mice heterozygous for a deficiency of
PPAR (PPAR/	) were significantly more susceptible to the
development of experimental colitis when compared with wild
type mice (42, 50, 51), and accordingly, PPAR expression in
colonic epithelium was substantially reduced in patients with
ulcerative colitis (52) as well as dextran sodium sulfate-treated
mice (53). Interestingly, Bacteroides thetaiotaomicron triggered
PPAR-mediated nuclear export of transcriptionally active RelA
and directly abolished Salmonella enteriditis-induced inflamma-
tory effects in IEC (54). These results provide compelling evi-
dence that PPAR plays an important role in the regulation of
mucosal inflammation. Taken together, two mechanisms are ap-
parent from these studies. First, PPAR inhibits inflammatory
processes in a ligand-independent manner, and second, PPAR
agonists inhibit NF-B activity as well as experimental colitis
through PPAR-independent mechanisms. Consistent with pre-
viously published results (54), we demonstrate that B. vulgatus
monoassociation of germ-free Fisher rats triggered persistent
nuclear but not cytoplasmic expression of the transcription factor
PPAR in the middle/upper part of the crypts of IEC from large
intestinal epithelium. In addition, we show that 15d-PGJ2 but
not synthetic TZD inhibits RelA phosphorylation and IL-6 gene
expression, confirming previously published results that demon-
strate different effects between 15d-PGJ2 and synthetic TZD (38,
55, 56). It remains to be seen whether PPAR expression is
directly involved in the negative regulation of B. vulgatus-in-
duced NF-B signal transduction in the intestinal epithelium.
We also demonstrate that 15d-PGJ2 but not the synthetic
high affinity ligand rosiglitazone triggered ERK1/2 phospho-
rylation in CMT-93 cells and, most importantly, MEK1 inhib-
itor PD98059 reversed LPS-induced RelA phosphorylation and
IL-6 gene expression in CMT-93 cells. Gilroy et al. (43) show in
a model for carrageenan-induced acute inflammation that heal-
ing and survival in these mice during the resolution phase of
inflammation were associated with increased levels of 15d-
PGJ2 and decreased levels of PGE2 (43). Concordently, we show
no inhibitory effects of PGE2 on LPS-induced RelA phosphoryl-
ation and IL-6 gene expression in CMT-93 cells. Furthermore,
previous studies demonstrated that 15d-PGJ2, which has no
known plasma membrane receptor, activates the MEK/ERK
signaling cascade through different mechanisms in various cell
types including superoxide anion-dependent induction of the
Raf/MEK-signaling pathway in myoblasts (48) as well as in-
duction of the phosphatidylinositol 3-kinase pathway in smooth
FIG. 6. The inhibitory effect of 15d-PGJ2 on LPS-induced RelA
phosphorylation and IL-6 gene expression was reversed in the
presence of PD98059. CMT-93 cells were stimulated with E. coli LPS
(10 g/ml) for 1 h in the presence or absence of 20 M 15d-PGJ2. Where
indicated the cells were pretreated for 1 h with 50 M PD98059. Total
protein was extracted, and 20 g of protein were subjected to SDS-
PAGE followed by phospho-ERK1/2, ERK1/2, phospho-RelA, and RelA
immunoblotting using an ECL technique (A). CMT-93 cells were stim-
ulated with E. coli LPS (10 g/ml) for 12 h in the presence or absence of
20 M 15d-PGJ2. Where indicated the cells were pretreated for 1 h with
50 M PD98059. Total RNA was extracted after 12 h of stimulation and
reverse-transcribed, and real-time PCR was performed using the Light
Cycler system with specific primers for murine IL-6 and GAPDH. The
induction of IL-6 mRNA expression was calculated relative to untreated
controls (fold increase) using the crossing point of the log-linear portion
of the amplification curve after normalization with GAPDH. The bars
represent the combined mean values (S.D.) of triplicate samples. *, p
value 0.05.
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muscle cells (57). Inhibition of LPS-induced NF-B activity in
the presence of 15d-PGJ2 was demonstrated in native and
macrophage cell lines at the level of IKK activity, IB deg-
radation, and NF-B DNA binding activity as well as chemo-
kine expression (55, 56, 58). Interestingly, we show that 15d-
PGJ2 does not affect LPS-induced IB phosphorylation/
degradation, IB resynthesis, and RelA nuclear translocation
in CMT-93 cells. It seems also unlikely that the slight delay in
LPS-induced RelA DNA binding activity fully accounts for the
complete inhibition of IL-6 gene expression in IEC but, rather,
suggests that the 15d-PGJ2-mediated inhibition of RelA phos-
phorylation directly affects IL-6 gene expression.
Phosphorylation and dephosphorylation of transcription fac-
tors regulates their DNA binding properties as well as their
transactivating potential, and apparently, complexes contain-
ing both protein kinases and phosphoprotein phosphatases are
important in maintaining the phosphorylation state of intra-
cellular substrates. PP2A, which regulates a diverse set of
cellular processes including signal transduction and transcrip-
tion, constitutively associates with RelA in the cytoplasm (24,
25). Calyculin A, which is a serine/threonine phosphatase in-
hibitor, increased base levels of phospho-RelA in untreated
CMT-93 cells, suggesting that the basal phosphatase activity
has to be relatively active to maintain a low state of phospho-
rylated RelA in IEC. Upon stimulation of CMT-93 cells with
LPS, the constitutive cycle of phosphorylation/dephosphoryl-
ation is disrupted presumably through induction of IKK, ca-
sein kinase, or phosphatidylinositol 3-kinase/Akt activity, re-
sulting in RelA serine phosphorylation (Ser-536). Most
importantly, calyculin A, which has higher inhibitory efficiency
for PP2A than for PP1 or PP2B, reversed the inhibitory effects
of 15d-PGJ2 on LPS-induced RelA dephosphorylation and IL-6
gene expression in CMT-93 cells. Based on these results, we
then show for the first time that immunoprecipitated PP2A
from 15d-PGJ2-treated CMT-93 cells directly dephosphorylates
endogenous RelA (Ser-536) from LPS-treated cells, suggesting
that 15d-PGJ2 triggered PP2A activity in epithelial cells. It is
not clear whether PP2A binds to the RelA serine phosphoryl-
ation sites, but studies on the interaction of PP2A with protein
kinase C, casein kinase-2, and CXCR2 suggest that PP2A
binds to other sites than the phosphorylation sites in these
proteins (27–29).
Non-pathogenic enteric bacteria play an important role in
initiating and perpetuating chronic intestinal inflammation in
the susceptible host. It appears from our gnotobiotic studies in
normal animals that enteric non-pathogenic bacteria including
Gram-negative B. vulgatus (17, 22) and Gram-positive Entero-
coccus faecalis (59) trigger transient NF-B signaling in the
intestinal epithelium in normal rats and mice, respectively. In
these studies the physiological importance for the induction of
protective TGF-/Smad signaling was clearly demonstrated in
native IEC (59). Although TGF-/Smad signaling blocked non-
pathogenic bacteria-induced NF-B transcriptional activity
and IL-6 gene expression in IEC (22), the molecular mechanism
for this inhibitory effect was identified at the level of altered
of the amplification curve after normalization with GAPDH. The bars
represent the combined mean values (S.D.) of triplicate samples. *,
reduction; #, increase; p value0.05. B, CMT-93 cells were stimulated
for 1 h with either E. coli LPS (10 g/ml) or 20 M 15d-PGJ2. We then
immunoprecipitated phospho-RelA and PP2A from lysed cells using
A/G-agarose beads. To assay the phosphatase activity, 30 l of beads
from LPS-stimulated cells were co-incubated with 50 l of beads from
15d-PGJ2-treated cells. Reactions were stopped after 1, 2, and 4 h of
incubation at 37 °C with the addition 2 Laemmli sample buffer. Total
protein was extracted from beads and subjected to SDS-PAGE followed
by phospho-RelA, RelA, and PP2A immunoblotting using ECL tech-
nique (C).
FIG. 7. Calyculin A reversed the inhibitory effect of 15d-PGJ2
on LPS-induced RelA phosphorylation and IL-6 gene expression
in CMT-93 cells; 15d-PGJ2 triggers PP2A activity and directly
dephosphorylates RelA. CMT-93 cells were stimulated with E. coli
LPS (10 g/ml) for 1 h in the presence or absence of 20 M 15d-PGJ2.
Where indicated the cells were pretreated for 1 h with 5 nM calyculin A.
Total protein was extracted, and 20 g of protein were subjected to
SDS-PAGE followed by phospho-RelA, RelA, PP2A, and -actin immu-
noblotting using ECL technique (A). CMT-93 cells were stimulated with
E. coli LPS (10 g/ml) for 12 h in the presence or absence of 20 M
15d-PGJ2. Where indicated the cells were pretreated for 1 h with 1 nM
calyculin A. Total RNA was extracted after 12 h of stimulation and
reverse-transcribed, and real-time PCR was performed using the Light
Cycler system with specific primers for murine IL-6 and GAPDH. The
induction of IL-6 mRNA expression was calculated relative to untreated
controls (-fold increase) using the crossing point of the log-linear portion
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histone acetylation/phosphorylation rather than inhibition of
RelA phosphorylation. Based on the results of this study, we
may hypothesize that 15d-PGJ2-mediated ERK1/2 signaling
contributes to the inhibition of NF-B-dependent gene expres-
sion in IEC through directly acting at the level of RelA phos-
phorylation by modulating PP2A activity. An attractive hy-
pothesis is that under normal physiological conditions the
coordinate induction of various protective mechanisms in IEC
including TGF-/Smad as well as 15d-PGJ2/ERK signaling
helps to control NF-B activity after initial bacterial coloniza-
tion to maintain normal epithelial cell homeostasis in the in-
terplay with commensal bacteria.
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